Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Thread starter International: Top News And Analysis
Start date Aug 25, 2025

International: Top News And Analysis

Guest

Aug 25, 2025

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions and easier manufacturing.

Continue reading...

You must log in or register to reply here.

Facebook X Bluesky LinkedIn Reddit Pinterest Tumblr WhatsApp Email Link

Thread Information

Title: Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors

Prefix: N/A

Forum: World News

Start date: Aug 25, 2025

Last reply date: Aug 25, 2025

Replies: 0

Thread Tags

Thread statistics

Created: International: Top News And Analysis, Aug 25, 2025

Replies: 0

Views: 14

About Us

XenTR Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout.

Color picker

Search